Galimedix Therapeutics

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

News

AZ seeking $1.5bn in annual savings by end-2029

AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks